Strides Pharma Science Share News - Latest Updates, Live News & More

Latest news about Strides Pharma Science

Strides Pharma Gets USFDA Closure Report for Chestnut Ridge Facility Inspection 6 days ago

Strides Pharma Science subsidiary received USFDA Inspection Closure Report for its Chestnut Ridge, New York facility with VAI classification. The inspection conducted from December 17-23, 2025, focused on cGMP compliance and pre-approval for drug-device combinations in nasal sprays domain, enhancing the company's U.S. manufacturing capabilities.

Strides Pharma Science Reports 127% Jump in Q3 Consolidated Net Profit to ₹2 Billion Jan 30, 2026

Strides Pharma Science Completes US-FDA Inspection, Receives Form 483 with Four Procedural Observations Dec 26, 2025

Strides Pharma Gets 4 FDA Observations, Reports 82% Jump in Q2 Net Profit Dec 24, 2025

Strides Pharma Reports Robust Q2 FY26 Results with 25.4% EBITDA Growth and Record Operational PAT Nov 05, 2025

More news about Strides Pharma Science

31Oct 25

Strides Pharma Science Reports Robust Q2 Performance with 81% Surge in Net Profit

Strides Pharma Science Limited posted strong Q2 results with an 81% year-over-year increase in consolidated net profit to ₹1.3 billion. Revenue grew 1.7% to ₹12.2 billion. EBITDA rose 25.4% to ₹2.32 billion, with margin expanding to 18.97%. The company's focus on Other Regulated Markets and profitability drove performance. Net debt reduced by ₹469m sequentially, demonstrating financial discipline.

17Oct 25

Strides Pharma Science Expands Women's Health Portfolio with WHO-Prequalified Contraceptive in Africa

Strides Pharma Science Limited has partnered with Incepta Pharmaceuticals to market the world's first WHO-prequalified generic version of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Africa. The product, branded as Medogen SubQ, is a three-month contraceptive that can be self-administered or given by healthcare workers. This collaboration aims to expand access to safe and affordable contraceptive options in underserved regions, addressing the needs of over 250 million women worldwide who lack access to modern contraception. The partnership aligns with Strides' strategic focus on women's health and its 'in Africa for Africa' approach.

08Sept 25

Strides Pharma Science Expands U.S. Nasal Spray Portfolio Through Kenox Partnership

Strides Pharma Science has formed a strategic partnership with Kenox Pharmaceuticals Inc. to develop multiple nasal spray products for the U.S. market. The collaboration aims to leverage Kenox's expertise in Orally Inhaled and Nasal Drug Products (OINDPs) and Strides' manufacturing and market presence. This move is expected to accelerate Strides' nasal spray offerings and strengthen its position in the U.S. pharmaceutical market. The partnership focuses on developing affordable, high-quality therapies across various therapeutic indications.

25Aug 25

Strides Pharma Science Streamlines Operations: Deregisters Non-Operating South African Subsidiary

Strides Pharma Science Limited has voluntarily deregistered its non-operating step-down subsidiary, Apollo Life Sciences Holdings (Pty) Ltd, in South Africa, effective August 22, 2025. This move is part of the company's strategy to streamline group entities and enhance operational efficiency. The deregistered subsidiary had minimal financial impact, with revenue of 0.22 million INR and a net worth of -0.02 million INR for the fiscal year ending March 31, 2025. The company has informed stock exchanges in compliance with SEBI regulations.

04Aug 25

Strides Pharma Reports Strong Q1 Results with 19.5% EBITDA Margin and 81% EPS Growth

Strides Pharma Science Limited reported robust Q1 financial results with revenue reaching ₹1,120.00 crores, gross margins expanding to 60%, and EBITDA margin improving to 19.5%. The company saw 7% year-on-year growth in the U.S. market, 9.2% growth in other regulated markets, and 32.2% growth in growth markets. Operational EPS grew by 81% to ₹12.40, while operating PAT hit a record ₹114.00 crores. The company maintains its $400 million U.S. revenue target by 2028 and is focusing on a 'beyond-generics' strategy, including nasal sprays, controlled substances, and patch products.

30Jul 25

Strides Pharma Projects Quarterly Operating Costs of ₹460-470 Crore, Aims for Debt Elimination in 3-4 Years

Strides Pharma Science Limited reported robust Q1 FY2026 results with 6.20% YoY revenue growth to ₹11,197.00 million and 80.60% YoY surge in operational PAT to ₹1,140.00 million. The company projects quarterly operating costs of ₹460-470 crore, a tax rate of 17-20%, and aims to eliminate debt within 3-4 years. EBITDA margin improved to 19.5%, and operational EPS reached ₹12.40. Management plans to enhance R&D efforts for long-term growth.

30Jul 25

Strides Pharma Reaffirms U.S. Revenue Target of $300-400 Million by 2028

Strides Pharma Science Limited has restated its goal to achieve U.S. revenue of $300-400 million by 2028, with expected gross margins of 58-60%. The company reported strong Q1 FY2026 results, including a 6.2% increase in revenue to ₹11,197.00 million and a 7% increase in U.S. revenue to $71 million. Strides' strategy includes expanding its product portfolio, maintaining market position, focusing on cost leadership, and investing in new segments. The company also reported improved profitability with an 80.6% increase in Operational PAT to ₹1,140.00 million.

29Jul 25

Strides Pharma Reports 7% US Sales Growth and Margin Expansion in June Quarter

Strides Pharma Science announced financial results showing a 6.2% year-over-year revenue increase to ₹1,119.70 crore. Gross margin expanded by 300 basis points to 60.3%. EBITDA grew 10% to ₹78.00 crore, with margin improving to 7%. US business revenue grew 7% to $70 million. The company recorded an exceptional loss of ₹8.40 crore and a one-time gain of ₹3,188.00 crore. Management expressed satisfaction with the results, citing cost management and execution. Shares traded 3.2% higher at ₹952.00 following the announcement.

22May 25

Strides Pharma Science Reports Strong Q4 Results with US Business Outperforming

Strides Pharma Science announced impressive Q4 results, with US business revenue reaching $291 million, a 21.80% year-over-year increase. Q4 EBITDA rose 6.37% to 2.17 billion rupees. Overall revenue grew 7.89% to 1160.20 crore Rs, while net profit surged 66.36% to 90.00 crore Rs. The company's EPS increased by 76.06% to 9.56 Rs. Despite strong performance, Strides cautioned about potential inconsistencies in growth markets over the next two years.

22May 25

Strides Pharma Science Ltd: Q4 Profit Soars, Outperforms Guidance

Strides Pharma Science announced strong Q4 results with revenue rising 14% to ₹1,190.00 crore and net profit soaring 722.1% to ₹85.60 crore. The US business grew by 23.2% to $77.00 million, while EBITDA increased 6.5% to ₹217.00 crore. Full-year revenue growth exceeded guidance at 17.2%. The company declared a dividend of ₹4.00 per share.

30Apr 25

Strides Pharma Bolsters Anti-Inflammatory Portfolio with FDA Approval for Celecoxib Capsules

Strides Pharma Science Limited has received USFDA approval for Celecoxib Capsules in 100 mg, 200 mg, and 400 mg strengths. The product, bioequivalent to Celebrex® Capsules, targets a US market worth $116 million. Manufactured in Puducherry, India, this approval enhances Strides' anti-inflammatory offerings. The company also recently acquired four ANDAs from Nostrum Laboratories for $2.08 million, further diversifying its US product portfolio.

29Apr 25

Strides Pharma Expands US Portfolio with $2.075 Million ANDA Acquisition

Strides Pharma Science's US subsidiary has acquired four approved ANDAs from Nostrum Laboratories for $2.08 million. The portfolio targets UTIs, pain management, allergy symptoms, and ADD/ADHD treatments, with a cumulative market size of $57 million. Two of the four ANDAs are expected to launch within 12 months, expanding Strides' portfolio of niche and difficult-to-manufacture products in the US market.

07Apr 25

Strides Pharma Recalls 4.4 Lakh Cartons of Testosterone Gel in US Market

Strides Pharma has initiated a recall of over 440,000 cartons of Testosterone Gel in the United States due to the detection of a foreign substance in the product. This recall demonstrates the company's commitment to patient safety and quality control. The incident may have short-term implications for Strides Pharma's revenue and market presence in the testosterone replacement therapy segment. The company has not yet released information about the financial impact or timeline for resolving the issue.

04Apr 25

Strides Pharma Recalls Over 440,000 Cartons of Testosterone Gel in US Market

Strides Pharma, Inc. has initiated a Class II recall of more than 440,000 cartons of Testosterone Gel in the United States due to benzene contamination. The recall affects two products: 195,952 cartons of 1% Testosterone Gel, 2.5 grams, and 244,412 cartons of 1% Testosterone Gel, 5 grams. The recall was initiated on March 5th in response to the detection of benzene, a known carcinogen not intended to be in the product. This situation may have implications for Strides Pharma's market position in the US and could lead to increased scrutiny of their manufacturing processes.

19Mar 25

Strides Pharma Science Unveils Strategic De-Merger Plan for Arco Lab's Life Sciences and Digital Innovation Business

Strides Pharma Science Limited's Board has approved the de-merger of its subsidiary Arco Lab's Life Sciences and Digital Innovation Capabilities into a new company (NewCo). The NewCo will be a wholly-owned subsidiary of Strides, focusing on Life Sciences and Manufacturing solutions. This restructuring aims to create a specialized entity without financial impact on Strides. Arco Lab will proceed with incorporating NewCo, drafting the scheme of arrangement, and conducting business valuation.

17Mar 25

Strides Pharma Science Subsidiary Eyes Southeast Asian Expansion with Amexel Acquisition

A subsidiary of Strides Pharma Science Ltd plans to acquire a 100% stake in Amexel Pte. Ltd., a Singapore-based company. This strategic move aims to strengthen Strides' presence in Southeast Asia and create a robust business platform in the region. The acquisition aligns with the growing pharmaceutical market in Southeast Asia, driven by increasing healthcare expenditure, population growth, and rising chronic diseases. While financial details remain undisclosed, this acquisition marks a significant step in Strides' international growth strategy.

14Mar 25

Strides Pharma Science Expands Footprint in Southeast Asia with Strategic Acquisition

Strides Pharma Science's subsidiary, Strides Pharma Global Pte. Limited, plans to acquire Amexel Pte. Ltd. for USD 10, aiming to strengthen its Southeast Asian presence. The acquisition, set to complete by March 31, 2025, focuses on technology transfer, supply chain enhancement, and market expansion. Amexel will operate on a revenue generation and profit-sharing model, facilitating partnerships and commercialization across the region.